First US Case of UK SARS-CoV-2 Variant Detected
First US Case of UK SARS-CoV-2 Variant Detected
Variant B.1.1.7, though likely more contagious than other strains, does not appear to be more deadly.
First US Case of UK SARS-CoV-2 Variant Detected
First US Case of UK SARS-CoV-2 Variant Detected

Variant B.1.1.7, though likely more contagious than other strains, does not appear to be more deadly.

Variant B.1.1.7, though likely more contagious than other strains, does not appear to be more deadly.

spike protein
UPDATED DEC 21
New SARS-CoV-2 Variant Spreading Rapidly in UK
New SARS-CoV-2 Variant Spreading Rapidly in UK
Max Kozlov | Dec 16, 2020
The significance of the variant remains unclear, but experts remain confident that it will not evade the protection offered by a COVID-19 vaccine.
The Promise of mRNA Vaccines
The Promise of mRNA Vaccines
Diana Kwon | Nov 25, 2020
Long before Moderna’s and Pfizer’s COVID-19 shots, scientists had been considering the use of genetically encoded vaccines in the fight against infectious diseases, cancer, and more.
Immunity to SARS-CoV-2 Lasts at Least Six Months, Data Show
Immunity to SARS-CoV-2 Lasts at Least Six Months, Data Show
Ashley Yeager | Nov 23, 2020
Half a year after infection, people who had recovered from COVID-19 had robust antibodies, along with traces of the virus in their gut, which may drive long-lasting immunity.
Scientists Probe Blockers for the Coronavirus Spike Protein
Scientists Probe Blockers for the Coronavirus Spike Protein
Anthony King | Nov 5, 2020
SARS-CoV-2, the virus that causes COVID-19, taps into human proteases such as furin to enter cells. Temporarily inhibiting those enzymes might stymie infection.
SARS-CoV-2 Antibody Durability
SARS-CoV-2 Antibody Durability
The Scientist Creative Services Team | Oct 2, 2020
Experts will discuss their research on SARS-CoV-2 antibody persistence and immune memory in recovered COVID-19 patients and the implications for protective immunity.
Vector-Based Vaccines Come to the Fore in the COVID-19 Pandemic
Vector-Based Vaccines Come to the Fore in the COVID-19 Pandemic
Anthony King | Sep 8, 2020
Adenovirus vectors deliver the genetic instructions for SARS-CoV-2 antigens directly into patients’ cells, provoking a robust immune response. But will pre-existing immunity from common colds take them down?
Modeling Study Flags Species Susceptible to SARS-CoV-2
Modeling Study Flags Species Susceptible to SARS-CoV-2
Anthony King | Aug 26, 2020
Some critically endangered animals are on the list.
Differences in Antibody Responses Linked to COVID-19 Outcomes
Differences in Antibody Responses Linked to COVID-19 Outcomes
Katarina Zimmer | Aug 18, 2020
In a small study of patients hospitalized due to SARS-CoV-2 infection, researchers report distinct early differences between the antibody responses of patients who recovered and those who died, possibly paving the way for a tool to predict disease prognosis.
First Antibody Trial Launched in COVID-19 Patients
First Antibody Trial Launched in COVID-19 Patients
Katarina Zimmer | Jun 2, 2020
In record time, scientists have gone from harvesting antibodies against SARS-CoV-2 from survivors of coronavirus infections to testing the antibodies’ safety as a drug in humans.